Molecular Tumor Board: 82-year-old female with high grade ovarian serous adenocarcinoma and BRCA1 F709fs mutation

An 82-year-old with advanced high-grade serous ovarian cancer and a BRCA1 mutation highlights the importance of somatic and germline testing to guide therapy and using PARP inhibitors for maintenance. Join our Molecular Tumor Board to explore treatment strategies and the impact of reversion mutations on resistance management.